These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22530051)

  • 1. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer.
    Kim RS; Avivar-Valderas A; Estrada Y; Bragado P; Sosa MS; Aguirre-Ghiso JA; Segall JE
    PLoS One; 2012; 7(4):e35569. PubMed ID: 22530051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers.
    Sanchez Calle A; Yamamoto T; Kawamura Y; Hironaka-Mitsuhashi A; Ono M; Tsuda H; Shimomura A; Tamura K; Takeshita F; Ochiya T; Yamamoto Y
    Mol Oncol; 2020 Sep; 14(9):2271-2287. PubMed ID: 32392629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular dormancy in minimal residual disease following targeted therapy.
    Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
    Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C; Benz CC
    Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.
    Straume O; Shimamura T; Lampa MJ; Carretero J; Øyan AM; Jia D; Borgman CL; Soucheray M; Downing SR; Short SM; Kang SY; Wang S; Chen L; Collett K; Bachmann I; Wong KK; Shapiro GI; Kalland KH; Folkman J; Watnick RS; Akslen LA; Naumov GN
    Proc Natl Acad Sci U S A; 2012 May; 109(22):8699-704. PubMed ID: 22589302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.
    Huang J; Woods P; Normolle D; Goff JP; Benos PV; Stehle CJ; Steinman RA
    Breast Cancer Res Treat; 2017 Jan; 161(2):229-243. PubMed ID: 27853906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding ER+ Breast Cancer Dormancy Using Bioinspired Synthetic Matrices for Long-Term 3D Culture and Insights into Late Recurrence.
    Ovadia EM; Pradhan L; Sawicki LA; Cowart JE; Huber RE; Polson SW; Chen C; van Golen KL; Ross KE; Wu CH; Kloxin AM
    Adv Biosyst; 2020 Sep; 4(9):e2000119. PubMed ID: 32603024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
    Amin R; Morita-Fujimura Y; Tawarayama H; Semba K; Chiba N; Fukumoto M; Ikawa S
    Mol Oncol; 2016 Apr; 10(4):575-93. PubMed ID: 26704768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
    West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
    Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
    [No Abstract]   [Full Text] [Related]  

  • 15. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
    Yu K; Ganesan K; Miller LD; Tan P
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3288-96. PubMed ID: 16740749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of biological pathways involved in chemotherapy response in breast cancer.
    Tordai A; Wang J; Andre F; Liedtke C; Yan K; Sotiriou C; Hortobagyi GN; Symmans WF; Pusztai L
    Breast Cancer Res; 2008; 10(2):R37. PubMed ID: 18445275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer.
    Fukuoka M; Ichikawa Y; Osako T; Fujita T; Baba S; Takeuchi K; Tsunoda N; Ebata T; Ueno T; Ohno S; Saitoh N
    Cancer Sci; 2022 Jul; 113(7):2336-2351. PubMed ID: 35415910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of breast tumor growth and metastasis by an engineered transcription factor.
    Beltran AS; Russo A; Lara H; Fan C; Lizardi PM; Blancafort P
    PLoS One; 2011; 6(9):e24595. PubMed ID: 21931769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
    Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.